07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

PulmoXen: Phase I data

An open-label, Russian Phase I trial in 12 healthy volunteers showed that once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez, which conducted the trial, plans to start...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

PulmoXen: Phase I started

Xenetic said Pharmsynthez began an open-label, Russian Phase I trial to evaluate 2,500 and 5,000 units of PulmoXen in 12 healthy volunteers. Xenetic (formerly Lipoxen plc ) has rights to develop and commercialize PulmoXen outside...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Opko, Pharmsynthez deal

Opko acquired about a 10% stake in Russian pharmaceutical company Pharmsynthez. Opko said it made the investment alongside of Russian nanotechnology fund Rusnano, which invested about RUR820 million ($26.2 million). Opko said it and Rusnano...